Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Tumors × camrelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4 Triple Negative Breast Neoplasms 3 Stomach Neoplasms 3 Nasopharyngeal Carcinoma 3 Lung Neoplasms 3 Uterine Cervical Neoplasms 2 Solid Tumor 2 Sarcoma 2 Esophageal Neoplasms 2 Breast Neoplasms 2 Advanced Solid Tumors 2 Thoracic Neoplasms 1 Small Cell Lung Carcinoma 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Recurrence 1 Pancreatic Neoplasms 1 PD-L1 Positive Non-small Cell Lung Cancer 1 Non-squamous Non-small-cell Lung Cancer 1 Non-squamous Non-small Cell Lung Cancer 1 Non Squamous Non Small Cell Lung Cancer 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Lymphoma, Extranodal NK-T-Cell 1 Lung Diseases 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Gastrointestinal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1

Interventions

camrelizumab 1 Radiotherapy 1 Nivolumab 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05799183 2024-12-31

A SHR-1210 BE Study on Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡